N/A N=36 CAE for Poorly Adherent Individuals With Schizophrenia
Schizophrenia
Primary: Average Number of CAE-S Sessions Attended by Those in the CAE-S Group After 12 Weeks — 4.89 Number of sessions attended
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
N/A N=233 Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts
Asthma
Primary: Chest Wall Muscle Size — 95.49; 97.82; 87.98; 102.86 cm2
N/A N=50 CLARE Mobile App for Caregiver Training and Support
Caregivers · Technology
Primary: Number of Participants Who Agreed to Participate — 50 Participants
N/A N=106 Addressing Insufficient PAP Use in Older Veterans
Sleep Apnea
Primary: PAP Adherence — 2.16; 0.87 hours per night — p=.0001
Phase 3 N=153 The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
Ichthyosis
Primary: Change in Investigator Global Assessment (IGA) Score — 41.4; 44.9 percentage of responders — p=0.39
Phase 3 N=450 XG005 for Pain Control in Subjects Undergoing Bunionectomy
Acute Pain
Primary: Compared the Summed Pain Intensity From the End of Surgery to 48 Hours (SPI48) Between the High-dose XG005 Group and the Placebo Group Postoperatively. — 132.63; 285.99…
N/A N=67 BREATHE-Peds Pilot- II III Trial and Post Trial
Asthma in Children
Primary: Mean Asthma Control Questionnaire Score — 2.7; 2.63; 0.98; 0.82 score on a scale
Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications
Covid19
Primary: Total Number of Participants Randomized Within Each Appendix — 1800; 1331; 1407; 1459 Participants
N/A N=15 Presence or Absence of Blood in the GI Lumen
Upper GI Bleeding
Primary: Number of Participants With True Positive Results — 3 Participants
Phase 2 N=506 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
End-Stage Renal Disease · End-Stage Kidney Disease · Kidney Failure, Chronic
Primary: Time to First Arteriovenous Graft (AVG) Thrombosis Event — 23.80; 22.98; 30.17 events per 100 person-years — p=0.470
N/A N=219 Criminal Justice Coordinated Transitional Care
HIV · Hepatitis C · Substance Use Disorders
Primary: Feasibility Outcome: Number of Participants Who Are Enrolled and Complete the Baseline Study Assessment — 219 Participants
Phase 2 N=611 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Advanced Solid Tumors · Triple Negative Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator Assessment — 22.6; 25.8 Percentage of Participants
Phase 2 N=428 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
Dyslipidemia
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 — -31.19; -33.83; -41.09; -46.62 Percent Change (%) — p=< 0.001
Phase 2 N=60 Evaluation of AMG 714 for Vitiligo
Vitiligo
Primary: Proportion of Participants Achieving a ≥ 35% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI35) at Week 24 — 0.150; 0.053 Proportion of…